Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

Arrowhead Pharma Refinances to $400M Term Loan, Closes Nov. 2

Arrowhead Pharmaceuticals, Inc. filed a Form 8-K on November 4, 2026, disclosing that the company entered into an Amended and Restated Financing Agreement on November 2, 2026, replacing its existing senior secured term loans with a new $400.0 million credit facility administered by Sixth …

Nitish Kishor | 04 November 2026

Tronox Declares $0.05 Quarterly Cash Dividend, Payable Jan. 15

Tronox Holdings plc filed a Form 8-K with the SEC on November 4, 2026, reporting that its Board of Directors declared a quarterly cash dividend of $0.05 per share, payable on January 15, 2027, to shareholders of record as of November 16, 2026.

Aditi Sarkar | 04 November 2026

Westlake Corporation Reports Q3 2026 Earnings Results

Westlake Corporation filed a Form 8-K with the U.S. Securities and Exchange Commission on November 4, 2026, announcing the release of its 2026 third quarter results of operations and financial condition.

Anjali Anand | 04 November 2026

Westlake Chemical Partners Reports Q3 2026 Results

Westlake Chemical Partners LP filed a Form 8-K with the SEC on November 4, 2026, announcing the release of its third quarter 2026 financial results and an accompanying conference call held the same day.

Anjali Anand | 04 November 2026

Latham Group Posts Q3 2026 Net Sales of $182.2 Million

Latham Group, Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 4, 2026, covering the fiscal quarter and three fiscal quarters ended September 26, 2026.

Aakashdeep | 04 November 2026

FIS Files 8-K for Q3 2026 Earnings and Full-Year Guidance

Fidelity National Information Services, Inc. filed a Form 8-K on November 4, 2026, announcing financial results for the three and nine months ended September 30, 2026, and providing guidance for the full year ending December 31, 2026.

Aditi Sarkar | 04 November 2026

Rapport Therapeutics Files Q3 2026 10-Q With 59.28M Shares Out

Rapport Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing its financial position and operational status as a clinical-stage biotechnology company.

Vinay Lochav | 04 November 2026

uniQure Q3 2026: Total Assets Rise to $940.6 Million

uniQure N.V. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter ended September 30, 2026, and reporting total assets of $940.6 million on its unaudited consolidated balance sheet.

Shwetambri Chauhan | 04 November 2026

Vishay Intertechnology Q3 2026: Net Revenues Hit $978.9M

Vishay Intertechnology, Inc. filed its Form 10-Q for the fiscal quarter ended October 3, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting a swing to profitability in the third quarter compared to a loss in the prior-year period.

Anjali Anand | 04 November 2026

Dine Brands Posts Q3 2026 10-Q With $91.1M Cash

Dine Brands Global, Inc. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter ended September 27, 2026.

Aakashdeep | 04 November 2026
Support

Hi! How can we help you today?

Loading…